<?xml version="1.0" encoding="UTF-8"?>
<p>HCV not only can lead to kidney disease [
 <xref rid="B6" ref-type="bibr">6</xref>â€“
 <xref rid="B12" ref-type="bibr">12</xref>], but also contributes to increased morbidity and mortality in patients with established CKD [
 <xref rid="B13" ref-type="bibr">13</xref>]. Kidney transplantation is recognized as the renal replacement therapy of choice for eligible patients with end-stage renal disease (ESRD) [
 <xref rid="B14" ref-type="bibr">14</xref>]. Some studies have shown better survival in HCV-positive kidney transplant recipients than in HCV-positive patients with ESRD who are on dialysis [
 <xref rid="B15" ref-type="bibr">15</xref>]. The optimal immunosuppressive regimen in this group of patients remains uncertain [
 <xref rid="B15" ref-type="bibr">15</xref>].
</p>
